Skip to main content
Repare Therapeutics Inc. logo

Repare Therapeutics Inc. — Investor Relations & Filings

Ticker · RPTX ISIN · US7602731025 US Professional, scientific and technical activities
Open in API
Filings indexed 420 across all filing types
Latest filing 2021-11-01 Capital/Financing Update
Country US United States of America
Listing US RPTX

About Repare Therapeutics Inc.

https://www.reparerx.com/

Repare Therapeutics Inc. is a clinical-stage precision oncology company that develops novel medicines using a proprietary synthetic lethality approach. The company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies. This platform supports a pipeline of product candidates aimed at treating cancers with specific genetic alterations and addressing high unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content describes the entry into a material definitive agreement related to an underwritten public offering of common shares, including details about the underwriting agreement, pricing, and net proceeds. It also references press releases about the offering. There are no financial statements or detailed financial performance data included, only an announcement of a financing event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is 5941 characters, sufficient to provide substantive details about the financing event, not just a brief announcement. Therefore, the correct classification is CAP with high confidence.
2021-11-01 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-10-29 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details a public offering of common shares, including the number of shares, pricing, underwriting commissions, and use of proceeds. The document includes sections typical of a prospectus supplement such as risk factors, company overview, recent developments, and clinical trial updates. It is not a financial report, earnings release, or management discussion but rather a capital raising document describing the terms of a securities offering. Therefore, it fits the definition of a Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or a brief summary.
2021-10-28 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to a $75 million offering of common shares by Repare Therapeutics Inc. It includes detailed information about the offering, risk factors, use of proceeds, underwriting, and company overview. The document is a registration and offering document for capital raising purposes, not a financial report, earnings release, or management discussion. It is clearly a capital markets filing related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, consistent with a capital raising update rather than a brief announcement or regulatory filing. Confidence is high given the explicit nature of the document as a prospectus supplement for a share offering.
2021-10-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a press release about initial Phase 1 clinical data and an upcoming investor webcast presentation. It includes a reference to a press release as an exhibit and states that the information is furnished and not filed, indicating it is an announcement rather than a full report. The document does not contain detailed financial statements or substantive financial data, nor is it a transcript or management discussion. It is primarily a regulatory announcement of a clinical trial update and investor event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-10-08 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.